References
Anderson JL, Stewart JR, Perry BA, van Hamersfeld DD, Johnson TA, et al. Oral flecainide acetate for the treatment of ventricular arrhythmias. New England Journal of Medicine 305: 473–477, 1981
Becker JU. Determination of the plasma concentration of a new antiarrhythmic, flecainide, by high-performance liquid chromatography (HPLC): sample preparation using extraction columns. Journal of Clinical Chemistry and Clinical Biochemistry 22: 389–393, 1984
Bexton RS, Hellestrand KJ, Nathan AW, Spanell RHJ, Camm AJ. A comparison of the antiarrhythmic effects on AV junctional re-entrant tachycardia of oral and intravenous flecainide acetate. European Heart Journal 4: 92–102, 1983
Braun J, Kollert JR, Becker JU. Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. European Journal of Clinical Pharmacology 31: 711–714, 1987
Conard GJ, Cronheim GE, Klempt HW. Relationship between plasma concentrations and suppression of ventricular extra-systoles by flecainide acetate (R-818), a new antiarrhythmic, in patients. Arzneimittel-Forschung 32: 155–159, 1982
Conard GJ, Cronheim GE, Klempt HW, Ober RE. Human plasma pharmacokinetics of flecainide acetate (R-818), a new antiarrhythmic, following oral and intravenous doses. Clinical Pharmacology and Therapeutics 25: 218, 1979
Conard GJ, Ober RE. Metabolism of flecainide. American Journal of Cardiology 53: 41b–51b, 1984
Duff HJ, Roden DM, Maffucci RJ, Vesper BS, Conard GJ, et al. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. American Journal of Cardiology 48: 1113–1140, 1981
Fach WA, Mai BV, Preusler W, Becker HJ. Flecainide intoxication. Innere Medizin 11: 27–31, 1984
Franciosa JA, Wilen M, Weeks CE, Tanebaum R, Kvam DC, et al. Pharmacokinetics and haemodynamic effects of flecainide in patients with chronic low output heart failure. Journal of the American College of Cardiology 1: 699, 1984
Graben N. Entgiftung mit Hämoperfusion (Detoxification by haemoperfusion), pp. 201–216, Bindernagel, Friedberg/Hessen, 1980
Hodges M, Haugland JM, Granrud G, Conard GJ, Asinger RW, et al. Suppression of ventricular ectopic depolarization by flecainide acetate, a new antiarrhythmic agent. Circulation 65: 879–885, 1982
Johnston A, Carrington S, Turner P. Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. British Journal of Clinical Pharmacology 20: 333–338, 1985
Muhiddin KA, Johnston A, Turner P. The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. British Journal of Clinical Pharmacology 17: 447–451, 1984
Tjandramaga TB, Verbesselt R, van Hecken A, van Meile P, de Schepper PJ. Oral flecainide elimination kinetics: the effect of cimetidine. Circulation 68: 416, 1983
Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. Journal of Clinical Pharmacology 24: 129–147, 1984
Wurzberger R, Wittner E, Avenhaus H, Hennemann H, Becker JU. Haemoperfusion in flecainide intoxication. Klinische Wochenschrift 64: 442–444, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Braun, J., Kollert, J.R., Gessler, U. et al. Failure of Haemoperfusion to Reduce Flecainide Intoxication. Med Toxicol Adverse Drug Exp 2, 463–467 (1987). https://doi.org/10.1007/BF03259879
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259879